No Detail Found!

Impact of simultaneous presence of multiple PML-RARA isoforms on phenotype in patients with acute promyelocytic leukaemia

Author(s)
Emine Goktas Department of Medical Genetics, Faculty of Medicine, Necmettin Erbakan University,Konya,Turkiye
Ayse Gul Zamani Department of Medical Genetics, Faculty of Medicine, Necmettin Erbakan University,Konya,Turkiye
Mahmut Selman Yildirim Department of Medical Genetics, Faculty of Medicine, Necmettin Erbakan University,Konya,Turkiye
Sinan Demircioglu Department of Internal Medicine, Division of Haematology, Faculty of Medicine, Necmettin Erbakan University,Konya,Turkiye
Atakan Tekinalp Department of Internal Medicine, Division of Haematology, Faculty of Medicine, Necmettin Erbakan University,Konya,Turkiye
Ozcan Ceneli Department of Internal Medicine, Division of Haematology, Faculty of Medicine, Necmettin Erbakan University,Konya,Turkiye
Abstract
Objective: To determine the coexistence of multiple PML-RARA transcripts in adult APL (acute promyelotic leukaemia) patients, and its impact on the patients laboratory parameters, treatment responses, and prognoses. Study Design: Cross-sectional study. Place and Duration of the Study: Department of Medical Genetics, Medical Faculty of Necmettin Erbakan University, Konya, Turkiye, from January 2015 to March 2023. Methodology: The study group consisted of individuals diagnosed with APL. RNA isolation was performed by taking blood or bone marrow samples and the presence of breakpoints in PML-RARA bcr1, bcr2, and bcr3 was detected using the real-time PCR. However, the quanti cation of PML-RARA fusion transcripts cannot be provided using the utilised kit. Results: Twelve women and eight men were examined with a mean age of 38 years (range: 19-80), and 46.5 years (range: 22-60) were examined, respectively. When evaluating patients based on isoforms, it was found that 40% had multiple isoforms. Nineteen (95%) patients achieved haematologic remission after the treatment. Only one patient who had three di erent isoforms did not achieve remission. The estimated median survival for patients with a single isoform and those with multiple isoforms was 78.1 months (95% CI: 37.8-117.6) and 71.7 months (46.2-97.2), respectively. Two of the patients with multiple isoforms were lost in the early stage, whereas no early-stage mortality was recorded among patients with a single isoform. Conclusion: Identifying PML-RARA isoform subtypes is important for predicting prognosis and informing clinical follow-up.
Publication Details
Page(s) 1294-1298
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 34, Issue: 11, Year: 2024

Request the full text from PASTIC

Keywords
Acute promyelocytic leukaemia, Isoform, Breakpoint cluster region, PML-RARA
0

Citations

0

Downloads

171

Views